Your browser doesn't support javascript.
Reorganization of Substance Use Treatment and Harm Reduction Services During the COVID-19 Pandemic: A Global Survey.
Radfar, Seyed Ramin; De Jong, Cornelis A J; Farhoudian, Ali; Ebrahimi, Mohsen; Rafei, Parnian; Vahidi, Mehrnoosh; Yunesian, Masud; Kouimtsidis, Christos; Arunogiri, Shalini; Massah, Omid; Deylamizadeh, Abbas; Brady, Kathleen T; Busse, Anja; Potenza, Marc N; Ekhtiari, Hamed; Baldacchino, Alexander Mario.
  • Radfar SR; Department of Neuroscience and Addiction, School of Advanced Technologies in Medicine (SATiM), Tehran University of Medical Sciences, Tehran, Iran.
  • De Jong CAJ; Integrated Substance Abuse Programs Department, University of California, Los Angeles, Los Angeles, CA, United States.
  • Farhoudian A; Behavioral Science Institute Radboud University, Nijmegen, Netherlands.
  • Ebrahimi M; Department of Psychiatry, Tehran University of Medical Sciences, Tehran, Iran.
  • Rafei P; Materials and Energy Research Center, Tehran, Iran.
  • Vahidi M; Iranian National Center for Addiction Studies, Tehran University of Medical Sciences, Tehran, Iran.
  • Yunesian M; Department of Psychology, Faculty of Psychology and Education, University of Tehran, Tehran, Iran.
  • Kouimtsidis C; Department of Psychiatry, Tehran University of Medical Sciences, Tehran, Iran.
  • Arunogiri S; School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
  • Massah O; Surrey and Borders Partnership NHS Foundation Trust, Leatherhead, United Kingdom.
  • Deylamizadeh A; Turning Point, Eastern Health, Box Hill, VIC, Australia.
  • Brady KT; Substance Abuse and Dependence Research Center, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran.
  • Busse A; Rebirth Charity Society NGO, Tehran, Iran.
  • Potenza MN; Staff Member of Prevention, Treatment and Rehabilitation Section, Drug Prevention and Health Branch, Division for Operations, United Nations Office on Drugs and Crime, Vienna, Austria.
  • Baldacchino AM; Connecticut Council on Problem Gambling and Connecticut Mental Health Center, Yale School of Medicine, New Haven, CT, United States.
Front Psychiatry ; 12: 639393, 2021.
Article in English | MEDLINE | ID: covidwho-1241207
Preprint
This scientific journal article is probably based on a previously available preprint. It has been identified through a machine matching algorithm, human confirmation is still pending.
See preprint
ABSTRACT

Background:

The coronavirus disease 2019 (COVID-19) pandemic has impacted people with substance use disorders (SUDs) worldwide, and healthcare systems have reorganized their services in response to the pandemic.

Methods:

One week after the announcement of the COVID-19 as a pandemic, in a global survey, 177 addiction medicine professionals described COVID-19-related health responses in their own 77 countries in terms of SUD treatment and harm reduction services. The health responses were categorized around (1) managerial measures and systems, (2) logistics, (3) service providers, and (4) vulnerable groups.

Results:

Respondents from over 88% of countries reported that core medical and psychiatric care for SUDs had continued; however, only 56% of countries reported having had any business continuity plan, and 37.5% of countries reported shortages of methadone or buprenorphine supplies. Participants of 41% of countries reported partial discontinuation of harm-reduction services such as needle and syringe programs and condom distribution. Fifty-seven percent of overdose prevention interventions and 81% of outreach services were also negatively impacted.

Conclusions:

Participants reported that SUD treatment and harm-reduction services had been significantly impacted globally early during the COVID-19 pandemic. Based on our findings, we highlight several issues and complications resulting from the pandemic concerning people with SUDs that should be tackled more efficiently during the future waves or similar pandemics. The issues and potential strategies comprise the following (1) helping policymakers to generate business continuity plans, (2) maintaining the use of evidence-based interventions for people with SUDs, (3) being prepared for adequate medication supplies, (4) integrating harm reduction programs with other treatment modalities, and (5) having specific considerations for vulnerable groups such as immigrants and refugees.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Observational study / Randomized controlled trials Language: English Journal: Front Psychiatry Year: 2021 Document Type: Article Affiliation country: Fpsyt.2021.639393

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Observational study / Randomized controlled trials Language: English Journal: Front Psychiatry Year: 2021 Document Type: Article Affiliation country: Fpsyt.2021.639393